Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Pharmion and MethylGene commence ‘important step’ in development of MGCD0103

Pharmion and MethylGene commence ‘important step’ in development of MGCD0103

11th October 2007

Pharmion and MethylGene have announced today the start of a Phase I trial evaluating Pharmion’s isotype-selective histone deacetylase inhibitor MGCD0103 in combination with Taxotere in patients with solid tumours.

Taxotere (docetaxel; Sanofi Aventis) is an already approved chemotherapy agent indicated for use in breast, prostate, gastric, lung, head and neck cancer.

The trial will see patients receive MGCD0103 orally three times a week for three weeks in combination with a dose of Taxotere on day one of the three-week cycle.

Pharmion has outlined three objectives of the study which include evaluating the safety of administering the agents together as well to determine the maximum tolerated dose of MGCD0103 in combination with Taxotere.

The final objective is to define optimal dosing in the second part of the trial which will see further assessment of the safety of the drug combination.

“This is an important step forward in the clinical development of MGCD0103,” said Andrew Allen, executive vice president and chief medical officer of Pharmion Corporation.

Pharmion is a global biotech company which works closely with the haematology and oncology communities to identify and develop products for global haematology and oncology markets.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.